nodes	percent_of_prediction	percent_of_DWPC	metapath
Emtricitabine—DCK—Doxorubicin—Epirubicin—bone cancer	0.0243	0.519	CbGdCrCtD
Emtricitabine—DCK—Epirubicin—Doxorubicin—bone cancer	0.0225	0.481	CbGdCrCtD
Emtricitabine—Hypokalaemia—Cisplatin—bone cancer	0.00586	0.00615	CcSEcCtD
Emtricitabine—Otitis media—Epirubicin—bone cancer	0.00585	0.00614	CcSEcCtD
Emtricitabine—Breast disorder—Cisplatin—bone cancer	0.00582	0.00611	CcSEcCtD
Emtricitabine—Nasopharyngitis—Cisplatin—bone cancer	0.00576	0.00604	CcSEcCtD
Emtricitabine—Rash pustular—Epirubicin—bone cancer	0.00571	0.006	CcSEcCtD
Emtricitabine—Neuritis—Doxorubicin—bone cancer	0.00565	0.00593	CcSEcCtD
Emtricitabine—Glycosuria—Epirubicin—bone cancer	0.00562	0.0059	CcSEcCtD
Emtricitabine—Proteinuria—Methotrexate—bone cancer	0.00554	0.00582	CcSEcCtD
Emtricitabine—Protein urine present—Methotrexate—bone cancer	0.00546	0.00574	CcSEcCtD
Emtricitabine—Pancreatitis—Cisplatin—bone cancer	0.00546	0.00573	CcSEcCtD
Emtricitabine—Otitis media—Doxorubicin—bone cancer	0.00541	0.00568	CcSEcCtD
Emtricitabine—Skin discolouration—Methotrexate—bone cancer	0.00539	0.00566	CcSEcCtD
Emtricitabine—Hyperbilirubinaemia—Methotrexate—bone cancer	0.00535	0.00562	CcSEcCtD
Emtricitabine—Rash pustular—Doxorubicin—bone cancer	0.00529	0.00555	CcSEcCtD
Emtricitabine—Glycosuria—Doxorubicin—bone cancer	0.0052	0.00546	CcSEcCtD
Emtricitabine—Skin discolouration—Epirubicin—bone cancer	0.00504	0.00529	CcSEcCtD
Emtricitabine—Inflammation—Methotrexate—bone cancer	0.00502	0.00527	CcSEcCtD
Emtricitabine—Hyperbilirubinaemia—Epirubicin—bone cancer	0.00501	0.00526	CcSEcCtD
Emtricitabine—Cough increased—Epirubicin—bone cancer	0.00498	0.00522	CcSEcCtD
Emtricitabine—Renal failure—Cisplatin—bone cancer	0.00488	0.00512	CcSEcCtD
Emtricitabine—Neuropathy peripheral—Cisplatin—bone cancer	0.00486	0.00511	CcSEcCtD
Emtricitabine—Creatinine increased—Epirubicin—bone cancer	0.00479	0.00502	CcSEcCtD
Emtricitabine—Bone pain—Epirubicin—bone cancer	0.00476	0.00499	CcSEcCtD
Emtricitabine—Inflammation—Epirubicin—bone cancer	0.0047	0.00493	CcSEcCtD
Emtricitabine—Hepatobiliary disease—Cisplatin—bone cancer	0.00469	0.00493	CcSEcCtD
Emtricitabine—Skin discolouration—Doxorubicin—bone cancer	0.00467	0.0049	CcSEcCtD
Emtricitabine—Hyperbilirubinaemia—Doxorubicin—bone cancer	0.00464	0.00487	CcSEcCtD
Emtricitabine—Cough increased—Doxorubicin—bone cancer	0.0046	0.00483	CcSEcCtD
Emtricitabine—Abnormal dreams—Epirubicin—bone cancer	0.0045	0.00473	CcSEcCtD
Emtricitabine—Creatinine increased—Doxorubicin—bone cancer	0.00443	0.00465	CcSEcCtD
Emtricitabine—Urine output increased—Methotrexate—bone cancer	0.0044	0.00462	CcSEcCtD
Emtricitabine—Bone pain—Doxorubicin—bone cancer	0.0044	0.00462	CcSEcCtD
Emtricitabine—Urinary tract disorder—Cisplatin—bone cancer	0.0044	0.00462	CcSEcCtD
Emtricitabine—Connective tissue disorder—Cisplatin—bone cancer	0.00438	0.0046	CcSEcCtD
Emtricitabine—Urethral disorder—Cisplatin—bone cancer	0.00437	0.00458	CcSEcCtD
Emtricitabine—Inflammation—Doxorubicin—bone cancer	0.00435	0.00456	CcSEcCtD
Emtricitabine—Neuropathy—Epirubicin—bone cancer	0.00428	0.00449	CcSEcCtD
Emtricitabine—Abnormal dreams—Doxorubicin—bone cancer	0.00417	0.00437	CcSEcCtD
Emtricitabine—Rash maculo-papular—Epirubicin—bone cancer	0.00414	0.00435	CcSEcCtD
Emtricitabine—Polyuria—Methotrexate—bone cancer	0.00402	0.00422	CcSEcCtD
Emtricitabine—Immune system disorder—Cisplatin—bone cancer	0.00402	0.00422	CcSEcCtD
Emtricitabine—Mediastinal disorder—Cisplatin—bone cancer	0.00402	0.00421	CcSEcCtD
Emtricitabine—Neuropathy—Doxorubicin—bone cancer	0.00396	0.00415	CcSEcCtD
Emtricitabine—Malnutrition—Cisplatin—bone cancer	0.00388	0.00407	CcSEcCtD
Emtricitabine—Rash maculo-papular—Doxorubicin—bone cancer	0.00383	0.00402	CcSEcCtD
Emtricitabine—Renal failure acute—Methotrexate—bone cancer	0.00383	0.00402	CcSEcCtD
Emtricitabine—Anaemia—Cisplatin—bone cancer	0.00358	0.00376	CcSEcCtD
Emtricitabine—Renal failure acute—Epirubicin—bone cancer	0.00358	0.00376	CcSEcCtD
Emtricitabine—Renal impairment—Epirubicin—bone cancer	0.00347	0.00365	CcSEcCtD
Emtricitabine—Dermatitis bullous—Epirubicin—bone cancer	0.00346	0.00363	CcSEcCtD
Emtricitabine—Renal failure acute—Doxorubicin—bone cancer	0.00331	0.00348	CcSEcCtD
Emtricitabine—Myalgia—Cisplatin—bone cancer	0.0033	0.00347	CcSEcCtD
Emtricitabine—Anxiety—Cisplatin—bone cancer	0.00329	0.00345	CcSEcCtD
Emtricitabine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.00328	0.00344	CcSEcCtD
Emtricitabine—Renal impairment—Doxorubicin—bone cancer	0.00322	0.00337	CcSEcCtD
Emtricitabine—Dermatitis bullous—Doxorubicin—bone cancer	0.0032	0.00336	CcSEcCtD
Emtricitabine—Breast disorder—Methotrexate—bone cancer	0.00319	0.00335	CcSEcCtD
Emtricitabine—Infection—Cisplatin—bone cancer	0.00314	0.0033	CcSEcCtD
Emtricitabine—Nervous system disorder—Cisplatin—bone cancer	0.0031	0.00326	CcSEcCtD
Emtricitabine—Thrombocytopenia—Cisplatin—bone cancer	0.0031	0.00325	CcSEcCtD
Emtricitabine—Blood creatinine increased—Epirubicin—bone cancer	0.0031	0.00325	CcSEcCtD
Emtricitabine—Skin disorder—Cisplatin—bone cancer	0.00307	0.00323	CcSEcCtD
Emtricitabine—Hypokalaemia—Epirubicin—bone cancer	0.00301	0.00316	CcSEcCtD
Emtricitabine—Pancreatitis—Methotrexate—bone cancer	0.00299	0.00314	CcSEcCtD
Emtricitabine—Breast disorder—Epirubicin—bone cancer	0.00299	0.00314	CcSEcCtD
Emtricitabine—Nasopharyngitis—Epirubicin—bone cancer	0.00296	0.0031	CcSEcCtD
Emtricitabine—Alanine aminotransferase increased—Epirubicin—bone cancer	0.00292	0.00306	CcSEcCtD
Emtricitabine—Muscular weakness—Epirubicin—bone cancer	0.00292	0.00306	CcSEcCtD
Emtricitabine—Musculoskeletal discomfort—Cisplatin—bone cancer	0.00288	0.00303	CcSEcCtD
Emtricitabine—Blood creatinine increased—Doxorubicin—bone cancer	0.00287	0.00301	CcSEcCtD
Emtricitabine—Neutropenia—Methotrexate—bone cancer	0.00286	0.003	CcSEcCtD
Emtricitabine—Paraesthesia—Cisplatin—bone cancer	0.00284	0.00298	CcSEcCtD
Emtricitabine—Upper respiratory tract infection—Methotrexate—bone cancer	0.00284	0.00298	CcSEcCtD
Emtricitabine—Dyspnoea—Cisplatin—bone cancer	0.00282	0.00296	CcSEcCtD
Emtricitabine—Pancreatitis—Epirubicin—bone cancer	0.0028	0.00294	CcSEcCtD
Emtricitabine—Hypokalaemia—Doxorubicin—bone cancer	0.00278	0.00292	CcSEcCtD
Emtricitabine—Breast disorder—Doxorubicin—bone cancer	0.00277	0.0029	CcSEcCtD
Emtricitabine—Pneumonia—Methotrexate—bone cancer	0.00274	0.00288	CcSEcCtD
Emtricitabine—Nasopharyngitis—Doxorubicin—bone cancer	0.00274	0.00287	CcSEcCtD
Emtricitabine—Gastrointestinal disorder—Cisplatin—bone cancer	0.00273	0.00287	CcSEcCtD
Emtricitabine—Infestation NOS—Methotrexate—bone cancer	0.00272	0.00286	CcSEcCtD
Emtricitabine—Infestation—Methotrexate—bone cancer	0.00272	0.00286	CcSEcCtD
Emtricitabine—Depression—Methotrexate—bone cancer	0.00272	0.00285	CcSEcCtD
Emtricitabine—Pain—Cisplatin—bone cancer	0.00271	0.00284	CcSEcCtD
Emtricitabine—Muscular weakness—Doxorubicin—bone cancer	0.0027	0.00283	CcSEcCtD
Emtricitabine—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.0027	0.00283	CcSEcCtD
Emtricitabine—Renal failure—Methotrexate—bone cancer	0.00268	0.00281	CcSEcCtD
Emtricitabine—Neutropenia—Epirubicin—bone cancer	0.00267	0.00281	CcSEcCtD
Emtricitabine—Upper respiratory tract infection—Epirubicin—bone cancer	0.00266	0.00279	CcSEcCtD
Emtricitabine—Haematuria—Methotrexate—bone cancer	0.0026	0.00273	CcSEcCtD
Emtricitabine—Pancreatitis—Doxorubicin—bone cancer	0.00259	0.00272	CcSEcCtD
Emtricitabine—Weight decreased—Epirubicin—bone cancer	0.00259	0.00271	CcSEcCtD
Emtricitabine—Hyperglycaemia—Epirubicin—bone cancer	0.00258	0.00271	CcSEcCtD
Emtricitabine—Hepatobiliary disease—Methotrexate—bone cancer	0.00258	0.0027	CcSEcCtD
Emtricitabine—Pneumonia—Epirubicin—bone cancer	0.00256	0.00269	CcSEcCtD
Emtricitabine—Infestation NOS—Epirubicin—bone cancer	0.00255	0.00267	CcSEcCtD
Emtricitabine—Infestation—Epirubicin—bone cancer	0.00255	0.00267	CcSEcCtD
Emtricitabine—Renal failure—Epirubicin—bone cancer	0.00251	0.00263	CcSEcCtD
Emtricitabine—Body temperature increased—Cisplatin—bone cancer	0.0025	0.00263	CcSEcCtD
Emtricitabine—Neuropathy peripheral—Epirubicin—bone cancer	0.0025	0.00262	CcSEcCtD
Emtricitabine—Urinary tract infection—Epirubicin—bone cancer	0.00248	0.0026	CcSEcCtD
Emtricitabine—Neutropenia—Doxorubicin—bone cancer	0.00247	0.0026	CcSEcCtD
Emtricitabine—Upper respiratory tract infection—Doxorubicin—bone cancer	0.00246	0.00258	CcSEcCtD
Emtricitabine—Hepatitis—Methotrexate—bone cancer	0.00244	0.00257	CcSEcCtD
Emtricitabine—Haematuria—Epirubicin—bone cancer	0.00243	0.00255	CcSEcCtD
Emtricitabine—Pharyngitis—Methotrexate—bone cancer	0.00243	0.00255	CcSEcCtD
Emtricitabine—Urinary tract disorder—Methotrexate—bone cancer	0.00241	0.00253	CcSEcCtD
Emtricitabine—Hepatobiliary disease—Epirubicin—bone cancer	0.00241	0.00253	CcSEcCtD
Emtricitabine—Urethral disorder—Methotrexate—bone cancer	0.0024	0.00252	CcSEcCtD
Emtricitabine—Weight decreased—Doxorubicin—bone cancer	0.00239	0.00251	CcSEcCtD
Emtricitabine—Sinusitis—Epirubicin—bone cancer	0.00239	0.00251	CcSEcCtD
Emtricitabine—Hyperglycaemia—Doxorubicin—bone cancer	0.00239	0.0025	CcSEcCtD
Emtricitabine—Pneumonia—Doxorubicin—bone cancer	0.00237	0.00249	CcSEcCtD
Emtricitabine—Infestation NOS—Doxorubicin—bone cancer	0.00236	0.00248	CcSEcCtD
Emtricitabine—Infestation—Doxorubicin—bone cancer	0.00236	0.00248	CcSEcCtD
Emtricitabine—Hypersensitivity—Cisplatin—bone cancer	0.00233	0.00245	CcSEcCtD
Emtricitabine—Renal failure—Doxorubicin—bone cancer	0.00232	0.00243	CcSEcCtD
Emtricitabine—Neuropathy peripheral—Doxorubicin—bone cancer	0.00231	0.00243	CcSEcCtD
Emtricitabine—Rhinitis—Epirubicin—bone cancer	0.00229	0.00241	CcSEcCtD
Emtricitabine—Urinary tract infection—Doxorubicin—bone cancer	0.00229	0.00241	CcSEcCtD
Emtricitabine—Hepatitis—Epirubicin—bone cancer	0.00229	0.0024	CcSEcCtD
Emtricitabine—Asthenia—Cisplatin—bone cancer	0.00227	0.00238	CcSEcCtD
Emtricitabine—Pharyngitis—Epirubicin—bone cancer	0.00227	0.00238	CcSEcCtD
Emtricitabine—Urinary tract disorder—Epirubicin—bone cancer	0.00226	0.00237	CcSEcCtD
Emtricitabine—Haematuria—Doxorubicin—bone cancer	0.00225	0.00236	CcSEcCtD
Emtricitabine—Connective tissue disorder—Epirubicin—bone cancer	0.00225	0.00236	CcSEcCtD
Emtricitabine—Urethral disorder—Epirubicin—bone cancer	0.00224	0.00235	CcSEcCtD
Emtricitabine—Hepatobiliary disease—Doxorubicin—bone cancer	0.00223	0.00234	CcSEcCtD
Emtricitabine—Sinusitis—Doxorubicin—bone cancer	0.00221	0.00232	CcSEcCtD
Emtricitabine—Immune system disorder—Methotrexate—bone cancer	0.00221	0.00232	CcSEcCtD
Emtricitabine—Mediastinal disorder—Methotrexate—bone cancer	0.0022	0.00231	CcSEcCtD
Emtricitabine—Diarrhoea—Cisplatin—bone cancer	0.00217	0.00227	CcSEcCtD
Emtricitabine—Mental disorder—Methotrexate—bone cancer	0.00214	0.00225	CcSEcCtD
Emtricitabine—Malnutrition—Methotrexate—bone cancer	0.00213	0.00223	CcSEcCtD
Emtricitabine—Rhinitis—Doxorubicin—bone cancer	0.00212	0.00223	CcSEcCtD
Emtricitabine—Hepatitis—Doxorubicin—bone cancer	0.00212	0.00222	CcSEcCtD
Emtricitabine—Pharyngitis—Doxorubicin—bone cancer	0.0021	0.00221	CcSEcCtD
Emtricitabine—Urinary tract disorder—Doxorubicin—bone cancer	0.00209	0.00219	CcSEcCtD
Emtricitabine—Connective tissue disorder—Doxorubicin—bone cancer	0.00208	0.00218	CcSEcCtD
Emtricitabine—Urethral disorder—Doxorubicin—bone cancer	0.00208	0.00218	CcSEcCtD
Emtricitabine—Immune system disorder—Epirubicin—bone cancer	0.00207	0.00217	CcSEcCtD
Emtricitabine—Mediastinal disorder—Epirubicin—bone cancer	0.00206	0.00216	CcSEcCtD
Emtricitabine—Back pain—Methotrexate—bone cancer	0.00206	0.00216	CcSEcCtD
Emtricitabine—Vomiting—Cisplatin—bone cancer	0.00201	0.00211	CcSEcCtD
Emtricitabine—Mental disorder—Epirubicin—bone cancer	0.002	0.0021	CcSEcCtD
Emtricitabine—Rash—Cisplatin—bone cancer	0.002	0.00209	CcSEcCtD
Emtricitabine—Dermatitis—Cisplatin—bone cancer	0.00199	0.00209	CcSEcCtD
Emtricitabine—Malnutrition—Epirubicin—bone cancer	0.00199	0.00209	CcSEcCtD
Emtricitabine—Anaemia—Methotrexate—bone cancer	0.00197	0.00206	CcSEcCtD
Emtricitabine—Back pain—Epirubicin—bone cancer	0.00193	0.00202	CcSEcCtD
Emtricitabine—Immune system disorder—Doxorubicin—bone cancer	0.00191	0.00201	CcSEcCtD
Emtricitabine—Mediastinal disorder—Doxorubicin—bone cancer	0.00191	0.002	CcSEcCtD
Emtricitabine—Nausea—Cisplatin—bone cancer	0.00188	0.00197	CcSEcCtD
Emtricitabine—Cough—Methotrexate—bone cancer	0.00186	0.00195	CcSEcCtD
Emtricitabine—Mental disorder—Doxorubicin—bone cancer	0.00185	0.00195	CcSEcCtD
Emtricitabine—Malnutrition—Doxorubicin—bone cancer	0.00184	0.00193	CcSEcCtD
Emtricitabine—Anaemia—Epirubicin—bone cancer	0.00184	0.00193	CcSEcCtD
Emtricitabine—Arthralgia—Methotrexate—bone cancer	0.00181	0.0019	CcSEcCtD
Emtricitabine—Myalgia—Methotrexate—bone cancer	0.00181	0.0019	CcSEcCtD
Emtricitabine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.0018	0.00189	CcSEcCtD
Emtricitabine—Back pain—Doxorubicin—bone cancer	0.00178	0.00187	CcSEcCtD
Emtricitabine—Cough—Epirubicin—bone cancer	0.00174	0.00182	CcSEcCtD
Emtricitabine—Infection—Methotrexate—bone cancer	0.00173	0.00181	CcSEcCtD
Emtricitabine—Nervous system disorder—Methotrexate—bone cancer	0.0017	0.00179	CcSEcCtD
Emtricitabine—Anaemia—Doxorubicin—bone cancer	0.0017	0.00179	CcSEcCtD
Emtricitabine—Thrombocytopenia—Methotrexate—bone cancer	0.0017	0.00178	CcSEcCtD
Emtricitabine—Arthralgia—Epirubicin—bone cancer	0.0017	0.00178	CcSEcCtD
Emtricitabine—Myalgia—Epirubicin—bone cancer	0.0017	0.00178	CcSEcCtD
Emtricitabine—Anxiety—Epirubicin—bone cancer	0.00169	0.00177	CcSEcCtD
Emtricitabine—Skin disorder—Methotrexate—bone cancer	0.00169	0.00177	CcSEcCtD
Emtricitabine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.00168	0.00177	CcSEcCtD
Emtricitabine—Infection—Epirubicin—bone cancer	0.00161	0.00169	CcSEcCtD
Emtricitabine—Cough—Doxorubicin—bone cancer	0.00161	0.00169	CcSEcCtD
Emtricitabine—Nervous system disorder—Epirubicin—bone cancer	0.00159	0.00167	CcSEcCtD
Emtricitabine—Thrombocytopenia—Epirubicin—bone cancer	0.00159	0.00167	CcSEcCtD
Emtricitabine—Musculoskeletal discomfort—Methotrexate—bone cancer	0.00158	0.00166	CcSEcCtD
Emtricitabine—Skin disorder—Epirubicin—bone cancer	0.00158	0.00166	CcSEcCtD
Emtricitabine—Insomnia—Methotrexate—bone cancer	0.00157	0.00165	CcSEcCtD
Emtricitabine—Myalgia—Doxorubicin—bone cancer	0.00157	0.00165	CcSEcCtD
Emtricitabine—Arthralgia—Doxorubicin—bone cancer	0.00157	0.00165	CcSEcCtD
Emtricitabine—Anxiety—Doxorubicin—bone cancer	0.00156	0.00164	CcSEcCtD
Emtricitabine—Paraesthesia—Methotrexate—bone cancer	0.00156	0.00164	CcSEcCtD
Emtricitabine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.00156	0.00164	CcSEcCtD
Emtricitabine—Dyspnoea—Methotrexate—bone cancer	0.00155	0.00163	CcSEcCtD
Emtricitabine—Dyspepsia—Methotrexate—bone cancer	0.00153	0.0016	CcSEcCtD
Emtricitabine—Gastrointestinal disorder—Methotrexate—bone cancer	0.0015	0.00157	CcSEcCtD
Emtricitabine—Fatigue—Methotrexate—bone cancer	0.0015	0.00157	CcSEcCtD
Emtricitabine—Infection—Doxorubicin—bone cancer	0.00149	0.00157	CcSEcCtD
Emtricitabine—Pain—Methotrexate—bone cancer	0.00149	0.00156	CcSEcCtD
Emtricitabine—Musculoskeletal discomfort—Epirubicin—bone cancer	0.00148	0.00155	CcSEcCtD
Emtricitabine—Nervous system disorder—Doxorubicin—bone cancer	0.00147	0.00155	CcSEcCtD
Emtricitabine—Thrombocytopenia—Doxorubicin—bone cancer	0.00147	0.00155	CcSEcCtD
Emtricitabine—Insomnia—Epirubicin—bone cancer	0.00147	0.00154	CcSEcCtD
Emtricitabine—Skin disorder—Doxorubicin—bone cancer	0.00146	0.00153	CcSEcCtD
Emtricitabine—Paraesthesia—Epirubicin—bone cancer	0.00146	0.00153	CcSEcCtD
Emtricitabine—Dyspnoea—Epirubicin—bone cancer	0.00145	0.00152	CcSEcCtD
Emtricitabine—Dyspepsia—Epirubicin—bone cancer	0.00143	0.0015	CcSEcCtD
Emtricitabine—Gastrointestinal pain—Methotrexate—bone cancer	0.00142	0.00149	CcSEcCtD
Emtricitabine—Gastrointestinal disorder—Epirubicin—bone cancer	0.0014	0.00147	CcSEcCtD
Emtricitabine—Fatigue—Epirubicin—bone cancer	0.0014	0.00147	CcSEcCtD
Emtricitabine—Pain—Epirubicin—bone cancer	0.00139	0.00146	CcSEcCtD
Emtricitabine—Urticaria—Methotrexate—bone cancer	0.00138	0.00145	CcSEcCtD
Emtricitabine—Abdominal pain—Methotrexate—bone cancer	0.00137	0.00144	CcSEcCtD
Emtricitabine—Body temperature increased—Methotrexate—bone cancer	0.00137	0.00144	CcSEcCtD
Emtricitabine—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.00137	0.00144	CcSEcCtD
Emtricitabine—Insomnia—Doxorubicin—bone cancer	0.00136	0.00143	CcSEcCtD
Emtricitabine—Paraesthesia—Doxorubicin—bone cancer	0.00135	0.00142	CcSEcCtD
Emtricitabine—Dyspnoea—Doxorubicin—bone cancer	0.00134	0.00141	CcSEcCtD
Emtricitabine—Gastrointestinal pain—Epirubicin—bone cancer	0.00133	0.0014	CcSEcCtD
Emtricitabine—Dyspepsia—Doxorubicin—bone cancer	0.00132	0.00139	CcSEcCtD
Emtricitabine—Gastrointestinal disorder—Doxorubicin—bone cancer	0.0013	0.00136	CcSEcCtD
Emtricitabine—Fatigue—Doxorubicin—bone cancer	0.0013	0.00136	CcSEcCtD
Emtricitabine—Urticaria—Epirubicin—bone cancer	0.00129	0.00136	CcSEcCtD
Emtricitabine—Pain—Doxorubicin—bone cancer	0.00129	0.00135	CcSEcCtD
Emtricitabine—Body temperature increased—Epirubicin—bone cancer	0.00128	0.00135	CcSEcCtD
Emtricitabine—Abdominal pain—Epirubicin—bone cancer	0.00128	0.00135	CcSEcCtD
Emtricitabine—Hypersensitivity—Methotrexate—bone cancer	0.00128	0.00134	CcSEcCtD
Emtricitabine—Asthenia—Methotrexate—bone cancer	0.00125	0.00131	CcSEcCtD
Emtricitabine—Gastrointestinal pain—Doxorubicin—bone cancer	0.00123	0.00129	CcSEcCtD
Emtricitabine—Pruritus—Methotrexate—bone cancer	0.00123	0.00129	CcSEcCtD
Emtricitabine—Hypersensitivity—Epirubicin—bone cancer	0.0012	0.00126	CcSEcCtD
Emtricitabine—Urticaria—Doxorubicin—bone cancer	0.00119	0.00125	CcSEcCtD
Emtricitabine—Abdominal pain—Doxorubicin—bone cancer	0.00119	0.00125	CcSEcCtD
Emtricitabine—Body temperature increased—Doxorubicin—bone cancer	0.00119	0.00125	CcSEcCtD
Emtricitabine—Diarrhoea—Methotrexate—bone cancer	0.00119	0.00125	CcSEcCtD
Emtricitabine—Asthenia—Epirubicin—bone cancer	0.00117	0.00122	CcSEcCtD
Emtricitabine—Pruritus—Epirubicin—bone cancer	0.00115	0.00121	CcSEcCtD
Emtricitabine—Dizziness—Methotrexate—bone cancer	0.00115	0.00121	CcSEcCtD
Emtricitabine—Diarrhoea—Epirubicin—bone cancer	0.00111	0.00117	CcSEcCtD
Emtricitabine—Hypersensitivity—Doxorubicin—bone cancer	0.00111	0.00116	CcSEcCtD
Emtricitabine—Vomiting—Methotrexate—bone cancer	0.0011	0.00116	CcSEcCtD
Emtricitabine—Rash—Methotrexate—bone cancer	0.0011	0.00115	CcSEcCtD
Emtricitabine—Dermatitis—Methotrexate—bone cancer	0.00109	0.00115	CcSEcCtD
Emtricitabine—Headache—Methotrexate—bone cancer	0.00109	0.00114	CcSEcCtD
Emtricitabine—Asthenia—Doxorubicin—bone cancer	0.00108	0.00113	CcSEcCtD
Emtricitabine—Dizziness—Epirubicin—bone cancer	0.00107	0.00113	CcSEcCtD
Emtricitabine—Pruritus—Doxorubicin—bone cancer	0.00106	0.00112	CcSEcCtD
Emtricitabine—Vomiting—Epirubicin—bone cancer	0.00103	0.00108	CcSEcCtD
Emtricitabine—Nausea—Methotrexate—bone cancer	0.00103	0.00108	CcSEcCtD
Emtricitabine—Diarrhoea—Doxorubicin—bone cancer	0.00103	0.00108	CcSEcCtD
Emtricitabine—Rash—Epirubicin—bone cancer	0.00102	0.00108	CcSEcCtD
Emtricitabine—Dermatitis—Epirubicin—bone cancer	0.00102	0.00107	CcSEcCtD
Emtricitabine—Headache—Epirubicin—bone cancer	0.00102	0.00107	CcSEcCtD
Emtricitabine—Dizziness—Doxorubicin—bone cancer	0.000995	0.00104	CcSEcCtD
Emtricitabine—Nausea—Epirubicin—bone cancer	0.000965	0.00101	CcSEcCtD
Emtricitabine—Vomiting—Doxorubicin—bone cancer	0.000956	0.001	CcSEcCtD
Emtricitabine—Rash—Doxorubicin—bone cancer	0.000948	0.000995	CcSEcCtD
Emtricitabine—Dermatitis—Doxorubicin—bone cancer	0.000947	0.000994	CcSEcCtD
Emtricitabine—Headache—Doxorubicin—bone cancer	0.000942	0.000989	CcSEcCtD
Emtricitabine—Nausea—Doxorubicin—bone cancer	0.000893	0.000938	CcSEcCtD
Emtricitabine—Zalcitabine—CYP3A4—bone cancer	0.000409	1	CrCbGaD
